^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Korlym (mifepristone)

    i
    Other names: C-1073, C1073
    Associations

    News

    Trials
    Company:
    Corcept Therap
    Drug class:
    Progesterone receptor antagonist, GCR II antagonist
    Related drugs:
    Associations

    News

    Trials
    11ms
    Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST) (clinicaltrials.gov)
    P4, N=1113, Completed, Corcept Therapeutics | Recruiting --> Completed | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: May 2024 --> Nov 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Korlym (mifepristone)
    12ms
    Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, University of Chicago | Trial completion date: Aug 2024 --> Aug 2026
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    albumin-bound paclitaxel • Korlym (mifepristone)
    12ms
    RESET-medication Glucocorticoid Receptor (GR) Blockade As Disease Modifying Treatment for Depression with Childhood Trauma (clinicaltrials.gov)
    P2, N=158, Completed, Amsterdam UMC, location VUmc | Recruiting --> Completed | Trial completion date: Jun 2024 --> Nov 2024 | Trial primary completion date: Dec 2023 --> Aug 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
    |
    Korlym (mifepristone) • Mifeprex (mifepristone)
    over1year
    INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers (clinicaltrials.gov)
    P1/2, N=65, Completed, Johns Hopkins University | Phase classification: P=N/A --> P1/2
    Phase classification
    |
    Korlym (mifepristone)
    almost2years
    Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST) (clinicaltrials.gov)
    P4, N=1000, Recruiting, Corcept Therapeutics | Trial primary completion date: Jan 2024 --> Mar 2024
    Trial primary completion date
    |
    Korlym (mifepristone)
    almost2years
    INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers (clinicaltrials.gov)
    P=N/A, N=65, Completed, Johns Hopkins University | Recruiting --> Completed | N=150 --> 65
    Trial completion • Enrollment change
    |
    Korlym (mifepristone)
    almost2years
    Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, University of Chicago | N=64 --> 29
    Enrollment change • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    albumin-bound paclitaxel • Korlym (mifepristone)
    2years
    A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=201, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • AR (Androgen receptor)
    |
    PD-L1 expression • HER-2 negative • AR positive
    |
    carboplatin • paclitaxel • capecitabine • Xtandi (enzalutamide) • Halaven (eribulin mesylate) • Korlym (mifepristone) • Mifeprex (mifepristone)
    almost3years
    Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=64, Active, not recruiting, University of Chicago | Trial primary completion date: Aug 2021 --> Dec 2022
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    albumin-bound paclitaxel • Korlym (mifepristone)
    almost3years
    GENETICALLY ENGINEERED HUMAN PITUITARY CORTICOTROPH TUMOR ORGANOIDS EXHIBIT DIVERGENT RESPONSES TO GLUCOCORTICOID RECEPTOR MODULATORS. (PubMed, Transl Res)
    Relacorilant sensitized PitNET organoid responsiveness to Pasireotide. Therefore, our study identified the potential therapeutic use of relacorilant in combination with somatostatin analogs and demonstrated the advantages of relacorilant over Mifepristone, supporting its further development for use in the treatment of CD patients.
    Journal
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5)
    |
    SSTR2 expression • SSTR5 expression
    |
    relacorilant (CORT125134) • Signifor (pasireotide) • Korlym (mifepristone) • Mifeprex (mifepristone)
    over3years
    Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=64, Active, not recruiting, University of Chicago | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2022 --> Aug 2021
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    albumin-bound paclitaxel • Korlym (mifepristone)